In the first instance if the continuing results from the RP11 trials prove to be as successful as we all expect, it will significantly reduce the company’s risk by validating both the drug and the Cell Penetrating Peptides (CPP) technology.
Then comes the money part. Securing a partnership during Phase 1/2,(RP11) which is feasible, could unlock a portion of the $1 billion market and provide substantial upfront revenue in the tens of millions. This financial boost would enhance our stability and potentially eliminate the need for additional capital raises, further de-risking our position.
With successful execution of this plan, the company’s market capitalisation could potentially reach multi-billion dollar levels over time.
I am nervous but quietly confident (well today anyway)
In the first instance if the continuing results from the RP11...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.020(1.74%) |
Mkt cap ! $659.0M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.13 | $187.3K | 162.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5698 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 938 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |